There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Biomea Fusion (BMEA – Research Report), Gritstone Oncology (GRTS – Research Report) and Organon (OGN – Research Report) with bullish sentiments.
Biomea Fusion (BMEA)
Barclays analyst Peter Lawson assigned a Buy rating to Biomea Fusion on March 1 and set a price target of $30.00. The company’s shares closed last Friday at $17.81.
According to TipRanks.com, Lawson is a 5-star analyst with an average return of
Biomea Fusion has an analyst consensus of Strong Buy, with a price target consensus of $54.43.
See the top stocks recommended by analysts >>
Organon (OGN)
In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Organon, with a price target of $26.00. The company’s shares closed last Friday at $17.56.
According to TipRanks.com, Prasad is a 4-star analyst with an average return of
Organon has an analyst consensus of Hold, with a price target consensus of $19.60.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BMEA:
- Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Biomea Fusion options imply 25.3% move in share price post-earnings
- BMEA Earnings this Week: How Will it Perform?
- Largest borrow rate increases among liquid names
- Dissecting My Biomea Fusion (NASDAQ:BMEA) Options Trade: Tips, Tricks, and Lessons Learned
